The Electrical Heart: Foundational Principles
Before we can understand why rhythms fail, we must understand why they succeed
Every heartbeat begins as an electrical impulse. This impulse must be generated (automaticity), conducted (propagation), and terminated (refractoriness). An arrhythmia occurs when any of these three fundamental processes fails. But why do they fail? To answer this, we must descend to the molecular level—to the ion channels that create the electrical language of the heart.
The cardiac action potential is not a single event but a precisely choreographed dance of ion channels opening and closing in sequence. Each channel has a specific role, a specific timing, and a specific vulnerability. When we understand this dance at the deepest level, arrhythmias cease to be mysterious—they become the predictable consequences of disrupted molecular physiology.
"The heart is a pump, but first it is an electrical organ. Every mechanical failure is preceded by an electrical failure."
— The Foundational Principle of Cardiac Electrophysiology
The heart must contract as a coordinated unit. Unlike skeletal muscle, where individual motor units can contract independently, the heart requires near-simultaneous activation of millions of cardiomyocytes. Without electrical coordination, the chambers would fibrillate—contracting in a chaotic, hemodynamically useless fashion.
Effective pumping requires sequential chamber activation: atria first (to fill the ventricles), then ventricles (to eject blood). Moreover, the ventricles must contract from apex to base to efficiently "squeeze" blood toward the outflow tracts. Random activation would produce zero net cardiac output despite consuming the same metabolic energy.
Electrical impulses travel through the heart via gap junctions—low-resistance channels connecting adjacent cardiomyocytes. This creates a functional syncytium where depolarization spreads from cell to cell like a wave. The conduction system (SA node → AV node → His-Purkinje) ensures the wave follows the correct path at the correct speed.
SA node: Fastest automaticity = physiological pacemaker. AV node: Slow conduction creates the AV delay, allowing atrial contraction to complete before ventricular activation. His-Purkinje: Rapid conduction ensures near-simultaneous activation of the entire ventricular myocardium (QRS <120ms).
Arrhythmias represent failures of initiation, conduction, or termination. Abnormal automaticity creates impulses from the wrong place. Conduction abnormalities create re-entry circuits or block. Failed refractoriness allows premature activation. Every arrhythmia mechanism maps to one of these fundamental failures.
Every cardiac arrhythmia results from one of three basic mechanisms: (1) Re-entry—the impulse travels in a circle; (2) Abnormal automaticity—ectopic pacemakers fire inappropriately; (3) Triggered activity—afterdepolarizations reach threshold. Understanding which mechanism underlies an arrhythmia determines its treatment.
Ion Channel Physiology: The Molecular Basis
Every cardiac action potential is created by ion channels opening and closing in precise sequence
Ion channels are transmembrane proteins that form pores allowing specific ions to cross the cell membrane. They are the fundamental units of cardiac electrophysiology. Each channel type has three critical properties: selectivity (which ion passes), gating (what opens/closes the channel), and conductance (how much current flows when open).
The resting cardiomyocyte maintains a membrane potential of approximately -90 mV (inside negative relative to outside). This potential is maintained by the differential distribution of ions across the membrane and the selective permeability to K+ at rest. Depolarization occurs when Na+ or Ca2+ channels open, allowing positive ions to rush into the cell.
Function: Rapid depolarization of working myocardium. When the cell reaches threshold (-70 mV), voltage-sensing domains trigger conformational change → channel opens → massive Na+ influx → membrane potential shoots toward +20 mV in <1 ms.
Gating: Three states—closed (resting), open (activated), inactivated (refractory). After opening, channels rapidly inactivate (within ms) and cannot reopen until repolarization restores the resting state.
Failure modes: Loss-of-function (Brugada syndrome)—reduced upstroke velocity, conduction slowing. Gain-of-function (LQT3)—persistent late Na+ current prolongs repolarization.
Function: Sustain depolarization during Phase 2 (plateau) and trigger excitation-contraction coupling. Ca2+ entry through L-type channels triggers Ca2+-induced Ca2+ release (CICR) from the sarcoplasmic reticulum.
Gating: Voltage-dependent activation (at ~-40 mV) but much slower kinetics than Na+ channels. Inactivation is both voltage-dependent and Ca2+-dependent (intracellular Ca2+ accelerates inactivation).
Failure modes: Gain-of-function (Timothy syndrome/LQT8)—prolonged Ca2+ current extends plateau, prolongs QT. Enhanced activity in heart failure increases triggered activity.
Function: Repolarization—returning the membrane to resting potential. Multiple K+ channel subtypes with different kinetics create the characteristic repolarization phases. IKr (rapid delayed rectifier), IKs (slow delayed rectifier), IK1 (inward rectifier).
Gating: IKr activates rapidly during plateau, drives Phase 3 repolarization. IKs activates slowly, provides repolarization reserve. IK1 maintains resting potential and contributes to terminal repolarization.
Failure modes: Loss-of-function (LQT1, LQT2)—reduced repolarization current prolongs action potential. Gain-of-function (Short QT syndrome)—accelerated repolarization shortens refractory period.
Function: Pacemaker depolarization in SA and AV nodes. Unlike other channels, HCN channels are activated by hyperpolarization (hence "funny"). They open during diastole when the membrane is most negative, generating the slow depolarization that drives automaticity.
Gating: Activated at potentials negative to -50 mV. Carry mixed Na+/K+ current that produces net inward (depolarizing) current. Modulated by cAMP—sympathetic stimulation increases cAMP → shifts activation → faster heart rate.
Failure modes: Loss-of-function—sinus bradycardia, sick sinus syndrome. Enhanced activity (inappropriate sinus tachycardia)—exaggerated heart rate response.
Ion channel dysfunction occurs through genetic mutations (channelopathies), acquired conditions (ischemia, drugs, electrolyte abnormalities), or structural remodeling (changes in channel expression or distribution). Each mechanism produces characteristic arrhythmia patterns.
Ion channels are complex proteins with multiple functional domains. Mutations can affect ion selectivity (wrong ion passes), gating kinetics (opens/closes at wrong time or rate), trafficking (channel doesn't reach membrane), or regulation (abnormal response to modulators). Each defect produces a specific electrophysiological signature.
Ischemia causes ATP depletion, which opens KATP channels (shortening action potential), impairs Na+/K+-ATPase (altering ionic gradients), and causes intracellular acidosis (which modifies channel gating). Elevated extracellular K+ from dying cells depolarizes surrounding tissue, inactivating Na+ channels and slowing conduction.
Many drugs bind to specific sites on ion channels. Some are therapeutic (antiarrhythmics), but many non-cardiac drugs inadvertently block cardiac channels. IKr (hERG channel) is particularly vulnerable because its inner pore has aromatic residues that bind many drug molecules—this is why drug-induced QT prolongation is so common.
The hERG channel has unique structural features: aromatic amino acids (Tyr and Phe) lining the inner cavity create binding sites for aromatic drug molecules. The channel's large central cavity accommodates diverse drug structures. Additionally, hERG lacks proline residues that in other K+ channels prevent drug access to the pore.
Hypokalemia prolongs repolarization by reducing K+ conductance and paradoxically reducing IKr (low extracellular K+ accelerates hERG channel inactivation). Hyperkalemia depolarizes the resting membrane, inactivating Na+ channels, slowing conduction, and potentially causing ventricular fibrillation. Hypomagnesemia destabilizes membranes and promotes triggered activity. Always check electrolytes in arrhythmia patients.
The Cardiac Action Potential: Phase by Phase
Understanding each phase reveals why specific interventions work
The cardiac action potential is not a simple spike like in neurons—it is a prolonged, plateau-shaped waveform lasting 200-400 ms. This extended duration is essential: it prevents re-excitation of tissue that has already contracted (ensuring unidirectional propagation) and it couples electrical activation to mechanical contraction through sustained Ca2+ entry.
Each phase represents a different balance of currents. At any moment, the membrane potential reflects the sum of all active ionic currents. When inward currents (Na+, Ca2+) dominate, the cell depolarizes. When outward currents (K+) dominate, the cell repolarizes. The transitions between phases occur when specific channels open or close.
In working myocardium (atria, ventricles): The resting membrane potential is stable at approximately -90 mV. This is maintained by IK1 (inward rectifier K+ current), which is highly active at negative potentials and keeps the cell at the K+ equilibrium potential. The cell remains quiescent until it receives an impulse from neighboring cells.
In pacemaker cells (SA node, AV node): Phase 4 is not stable—there is spontaneous diastolic depolarization. Multiple currents contribute: If (funny current) activates upon hyperpolarization and carries inward Na+/K+ current; ICa,T (T-type Ca2+ current) activates as the membrane approaches -50 mV; declining IK from the previous action potential also contributes. The slope of Phase 4 depolarization determines heart rate.
Why this matters: Sympathetic stimulation (β-adrenergic) increases cAMP, which shifts If activation positive and increases Ca2+ current → steeper Phase 4 slope → faster heart rate. Parasympathetic stimulation (muscarinic) activates IK,ACh and decreases If → shallower slope → slower heart rate. This is the molecular basis of autonomic heart rate control.
In working myocardium: When the cell reaches threshold (approximately -70 mV), voltage-gated Na+ channels undergo rapid conformational change and open. The resulting massive Na+ influx (INa) depolarizes the membrane from -90 mV toward +20-30 mV within <1 ms. The maximum rate of depolarization (dV/dtmax) can exceed 200 V/s in healthy Purkinje fibers.
In nodal tissue: SA and AV node cells have few Na+ channels; instead, Phase 0 is mediated by L-type Ca2+ channels. Because Ca2+ channels activate more slowly and conduct less current than Na+ channels, the upstroke is slower (dV/dtmax ~10 V/s) and reaches only ~+10 mV. This slow upstroke is why nodal conduction is slow—essential for AV delay.
Why this matters: dV/dtmax determines conduction velocity. Fast upstroke → strong electrical gradient → rapid spread to adjacent cells. Anything that reduces Na+ channel availability (ischemia, hyperkalemia, Class I antiarrhythmics) slows conduction. Slow conduction is a prerequisite for re-entry circuits.
Na+ channel states: After opening, Na+ channels rapidly inactivate (within 1-2 ms). Inactivated channels cannot reopen regardless of membrane potential—they must first recover through the closed state, which requires repolarization. This voltage-dependent recovery creates the effective refractory period.
The mechanism: Immediately after Phase 0, Na+ channels inactivate while the transient outward K+ current (Ito) activates. This K+ efflux causes a brief, partial repolarization—the "notch" between Phase 0 and the plateau. Ito then rapidly inactivates, allowing the plateau to begin.
Regional variation: Ito density varies significantly across the ventricular wall. Epicardial cells have high Ito density → prominent notch. Endocardial cells have low Ito density → minimal notch. This creates a transmural gradient in action potential morphology that is visible on ECG.
Why this matters: The transmural gradient creates the substrate for Brugada syndrome. Loss-of-function Na+ channel mutations reduce Phase 0 amplitude preferentially in epicardium (where Ito is already prominent). The resulting voltage gradient during Phase 1 creates an ECG pattern (coved ST elevation in V1-V3) and can trigger phase 2 re-entry → ventricular fibrillation.
Brugada syndrome deep mechanism: When epicardial Phase 0 is reduced (SCN5A mutation), the strong Ito causes marked early repolarization (loss of dome). Endocardium retains normal action potential. The resulting voltage gradient between epicardium and endocardium during early repolarization creates current flow that can trigger re-excitation of recovered epicardial tissue.
The delicate balance: The plateau represents a near-perfect balance between inward Ca2+ current (ICa,L) and gradually activating outward K+ currents (IKr, IKs). The membrane potential hovers around 0 to +20 mV for 150-300 ms. This is the longest phase and determines the duration of the QT interval.
Why the plateau exists: The plateau serves two critical functions. First, it allows sustained Ca2+ entry for excitation-contraction coupling—Ca2+ through L-type channels triggers Ca2+-induced Ca2+ release from the SR. Second, it provides the refractory period—as long as the cell is depolarized, Na+ channels remain inactivated and the cell cannot be re-excited.
Why this matters: The plateau is where most proarrhythmia occurs. Prolonged plateau (reduced K+ current or enhanced Ca2+/Na+ current) → Long QT syndrome → EADs → Torsades de Pointes. Shortened plateau (enhanced K+ current) → Short QT syndrome → short refractory period → re-entry → VF.
The L-type Ca2+ window current: L-type Ca2+ channels have overlapping activation and inactivation voltage ranges. In this "window" (approximately -30 to +10 mV), a small persistent inward current exists. If repolarization is delayed (long QT), cells spend more time in this window, increasing Ca2+ entry and promoting EADs.
The downstroke: As L-type Ca2+ channels progressively inactivate (both voltage-dependent and Ca2+-dependent inactivation), the balance shifts toward K+ currents. IKr (rapid delayed rectifier) is the dominant repolarizing current. As the membrane repolarizes past -40 mV, IK1 begins to contribute, accelerating terminal repolarization back to -90 mV.
Why IKr is so important: IKr (encoded by KCNH2/hERG) is the main driver of Phase 3. Loss-of-function mutations (LQT2) or drug block dramatically prolongs repolarization. Because hERG has unique structural properties that make it susceptible to drug binding, drug-induced QT prolongation is predominantly an IKr phenomenon.
Repolarization reserve: Multiple K+ currents contribute to repolarization: IKr, IKs, IK1. This redundancy provides "repolarization reserve"—if one current is reduced, others can compensate. However, when reserve is depleted (e.g., genetic IKs reduction + drug IKr block), repolarization fails catastrophically.
Why this matters: The concept of repolarization reserve explains why some patients tolerate QT-prolonging drugs while others develop Torsades de Pointes. Patients with subclinical channelopathies (reduced baseline IKs or IKr) have diminished reserve and are at higher risk of proarrhythmia when challenged with additional insults.
Absolute Refractory Period (ARP): No stimulus, regardless of strength, can trigger another action potential. Corresponds to Phase 0 through early Phase 3, when Na+ channels are inactivated. Effective Refractory Period (ERP): Period during which a propagated response cannot be elicited. Slightly longer than ARP. Relative Refractory Period (RRP): Strong stimuli can trigger action potentials, but they have reduced amplitude and slow conduction (because not all Na+ channels have recovered). This is the vulnerable period for re-entry initiation.
Re-entry: The Circular Impulse
The most common mechanism of sustained arrhythmias
Re-entry is not a disorder of impulse generation—it is a disorder of impulse propagation. In re-entry, an electrical impulse travels around a circuit, continually re-exciting tissue that has recovered from the previous activation. Once initiated, re-entry can be self-sustaining—each circuit completion generates the next, creating a persistent tachycardia.
Re-entry is responsible for the majority of clinically significant arrhythmias: AVNRT, AVRT (WPW), atrial flutter, typical VT, and the wavelet re-entry of atrial fibrillation. Understanding the requirements for re-entry reveals why it can be terminated by drugs, ablation, or pacing.
For re-entry to occur, three conditions must be satisfied simultaneously. If any one is eliminated, the circuit fails:
-
01
A Circuit (Anatomical or Functional)
There must be a pathway that allows the impulse to return to its starting point. This can be an anatomical circuit (fixed structure like an accessory pathway, scar border, or the AV node dual pathways) or a functional circuit (created by heterogeneous refractoriness or wavelength dynamics). The circuit must have sufficient length to accommodate the wavelength of the impulse. -
02
Unidirectional Block
The impulse must be blocked in one direction but conduct in the other. This asymmetry is essential—without it, impulses traveling in opposite directions would collide and extinguish. Unidirectional block typically occurs due to differential refractoriness: one pathway has a longer refractory period and is still refractory when the impulse arrives, while the other pathway has recovered and can conduct. -
03
Slow Conduction (Creating an Excitable Gap)
The impulse must travel slowly enough that by the time it completes the circuit, the tissue at the origin has recovered excitability. If conduction is too fast, the impulse arrives at tissue that is still refractory. The relationship is: Circuit length > Wavelength, where Wavelength = Conduction velocity × Refractory period. The difference between circuit length and wavelength creates the excitable gap—recoverable tissue ahead of the wavefront.
Without a circuit, an impulse propagates outward in all directions and then dies when it reaches inexcitable boundaries. A circuit provides a return pathway—the impulse can travel around and arrive back at tissue that has recovered. The circuit can be macroscopic (atrial flutter around the tricuspid annulus) or microscopic (rotors in AF).
If block were bidirectional, no conduction would occur through that pathway. If there were no block at all, impulses would travel both directions simultaneously, meet in the middle, and annihilate each other (collision). Unidirectional block ensures the impulse travels only one way around the circuit, preventing collision and allowing perpetual circulation.
Two pathways rarely have identical electrophysiological properties. Differences in refractory period duration are most common: a premature beat arrives when one pathway (longer ERP) is still refractory but the other (shorter ERP) has recovered. This differential refractoriness creates the asymmetry that allows unidirectional block. Structural factors (fibrosis, accessory pathways) can also create permanent unidirectional properties.
The impulse must "give time" for tissue to recover. Consider: if the impulse completes the circuit in 100 ms, but the refractory period is 200 ms, the impulse will find refractory tissue and die. The wavelength (conduction velocity Ă— refractory period) must be shorter than the circuit length. Slow conduction shortens the wavelength, increasing the probability that the circuit can accommodate it.
The excitable gap is the portion of the circuit that has recovered and is ready to conduct. A large excitable gap makes re-entry stable and difficult to terminate. A small excitable gap makes re-entry precarious—small changes in conduction velocity or refractory period can cause the wavefront to encounter refractory tissue. Antiarrhythmic drugs often work by shrinking the excitable gap (prolonging refractoriness) or eliminating unidirectional block.
Anatomical re-entry uses a fixed circuit defined by cardiac structures. Examples: AVRT (accessory pathway), AVNRT (dual AV nodal pathways), typical atrial flutter (around tricuspid annulus), post-infarct VT (around scar). The circuit location is predictable, making catheter ablation highly effective—destroy one part of the circuit, and re-entry becomes impossible.
Functional re-entry has no fixed anatomical circuit. The circuit is created dynamically by heterogeneous electrophysiological properties. The classic model is the leading circle: the impulse circulates around a core of functionally refractory tissue. A more contemporary model is the spiral wave (rotor): a curved wavefront rotates around a phase singularity. Functional re-entry is responsible for AF and is harder to ablate because the circuit location shifts.
AVNRT: Circuit involves slow and fast AV nodal pathways. Slow pathway has longer ERP but slower conduction. PAC blocks in fast pathway (still refractory), conducts down slow pathway, returns up fast pathway (now recovered). Ablation of slow pathway eliminates circuit. Atrial flutter: Macro-reentrant circuit around tricuspid annulus, with the cavotricuspid isthmus as the critical slow-conduction zone. Ablation of CTI creates bidirectional block, preventing flutter. VT post-MI: Circuit involves surviving myocardium channels within scar. The scar creates unidirectional block and slow conduction. Ablation targets the critical isthmus within the scar.
Abnormal Automaticity: Ectopic Pacemakers
When non-pacemaker tissue acquires the ability to fire spontaneously
Normal automaticity is the intrinsic ability of pacemaker cells (SA node, AV node, Purkinje fibers) to generate spontaneous impulses. This is a physiological property mediated by the gradual Phase 4 depolarization through If, ICa,T, and declining IK. The hierarchy (SA node fastest) ensures that faster pacemakers suppress slower ones through overdrive suppression.
Abnormal automaticity occurs when cells that are not normally automatic (working atrial or ventricular myocardium) develop spontaneous Phase 4 depolarization. This typically occurs when cells are partially depolarized (resting potential more positive than normal), which can unmask latent pacemaker currents or activate different ion channels.
When resting membrane potential rises from -90 mV to -60 mV (partial depolarization), several things change: IK1 (which normally stabilizes resting potential) becomes less active; If may contribute more; and ICa,L (L-type Ca2+ channels) may activate. The result is spontaneous diastolic depolarization in cells that are normally quiescent.
Common causes include: Ischemia—ATP depletion impairs Na+/K+-ATPase, allowing intracellular Na+ to rise and extracellular K+ to accumulate; the elevated extracellular K+ depolarizes surrounding cells. Electrolyte abnormalities—hyperkalemia directly depolarizes cells. Stretch—activates mechanosensitive channels. Catecholamines—enhance automatic currents.
Abnormal automatic foci can compete with or override the SA node, causing ectopic rhythms. Because the mechanism is abnormal impulse generation (not re-entry), these arrhythmias have characteristic features: they typically cannot be terminated by overdrive pacing or cardioversion, they show warm-up (gradual rate acceleration at onset), and they are often catecholamine-sensitive.
A related but distinct phenomenon is enhanced normal automaticity—increased firing rate of normal pacemaker cells. This can occur in SA node (sinus tachycardia from catecholamines or fever), AV junction (accelerated junctional rhythm), or Purkinje fibers (accelerated idioventricular rhythm). The mechanism is steepening of Phase 4 slope through increased If, increased ICa, or decreased IK.
Unlike abnormal automaticity, enhanced normal automaticity occurs at normal resting potentials. The clinical distinction matters because enhanced normal automaticity can be overdrive suppressed (the mechanism is normal, just accelerated), while abnormal automaticity often cannot.
AIVR is the classic example of enhanced Purkinje automaticity, commonly seen during reperfusion after MI. Mechanism: ischemia-reperfusion causes transient intracellular Ca2+ overload and catecholamine release, enhancing automaticity. Rate is typically 60-110 bpm (faster than normal ventricular escape but slower than VT). It is usually benign and self-limiting. Important to distinguish from VT: AIVR has gradual onset/offset (warm-up/cool-down), whereas re-entrant VT has abrupt onset/offset.
Triggered Activity: Afterdepolarizations
When repolarization itself triggers another action potential
Triggered activity is a hybrid mechanism—like automaticity, it involves spontaneous depolarization; like re-entry, it requires a preceding action potential. The key feature is the afterdepolarization: an abnormal depolarization that occurs during or after repolarization, triggered by the preceding action potential. If the afterdepolarization reaches threshold, it triggers another action potential, which can trigger another, creating a self-sustaining tachycardia.
There are two types: Early Afterdepolarizations (EADs) occur during Phase 2 or 3 (before repolarization is complete); Delayed Afterdepolarizations (DADs) occur during Phase 4 (after repolarization is complete). They have different mechanisms, different triggers, and different clinical associations.
An EAD is a secondary depolarization that occurs before repolarization is complete—typically during Phase 2 (plateau) or Phase 3 (rapid repolarization). On the action potential recording, it appears as a "hump" or oscillation superimposed on the repolarization phase. If the EAD reaches threshold, it triggers a new action potential.
EADs occur when repolarization is prolonged. The prolonged action potential allows time for L-type Ca2+ channels (or late Na+ channels) to recover from inactivation and reactivate. This "window current" phenomenon creates an inward current during the plateau that can trigger another upstroke. The longer the action potential, the greater the opportunity for channel recovery and reactivation.
L-type Ca2+ channels have voltage-dependent inactivation that recovers slowly at positive potentials. During a normal action potential, repolarization proceeds quickly enough that channels don't have time to recover. But if repolarization is prolonged (the cell spends more time at plateau voltages), channels progressively recover from inactivation. Once enough channels have recovered, the inward Ca2+ current exceeds outward K+ current → EAD.
Long QT syndrome (congenital or acquired) is defined by prolonged repolarization. LQT1 (reduced IKs), LQT2 (reduced IKr), and LQT3 (persistent late INa) all prolong the action potential, creating the substrate for EADs. Drug-induced QT prolongation (typically IKr block) creates the same substrate. The arrhythmia Torsades de Pointes is triggered by EADs and is the hallmark arrhythmia of long QT states.
Torsades ("twisting of the points") has a characteristic QRS axis that rotates around the baseline. This reflects shifting ventricular activation: the EAD-triggered impulses arise from different locations as the re-entry wavefront shifts. The EAD initiates the arrhythmia; subsequent beats may involve a combination of triggered activity and functional re-entry. The polymorphic morphology distinguishes it from monomorphic VT.
EADs are characteristically bradycardia-dependent or pause-dependent. Slow heart rates prolong diastole, which allows more time for repolarization (longer QT at slow rates). The "long-short" sequence is classic: a long pause (from bradycardia or a compensatory pause after a PVC) prolongs the subsequent QT, creating the substrate for an EAD. The EAD triggers a PVC, which creates another compensatory pause, and the cycle continues. This is why Torsades often emerges from bradycardia and why treatment includes increasing heart rate (pacing or isoproterenol).
A DAD is a transient depolarization that occurs after repolarization is complete—during Phase 4 (diastole). Unlike EADs, DADs arise from a fully repolarized membrane. They appear as small "humps" following the action potential. If the DAD reaches threshold, it triggers a premature action potential.
DADs are caused by intracellular Ca2+ overload. When cytoplasmic Ca2+ is excessive, the sarcoplasmic reticulum (SR) becomes overloaded. This leads to spontaneous Ca2+ release from the SR during diastole. The released Ca2+ activates the Na+/Ca2+ exchanger (NCX), which extrudes Ca2+ in exchange for Na+ (3 Na+ in for 1 Ca2+ out). This net inward current depolarizes the membrane → DAD.
The SR releases Ca2+ through ryanodine receptors (RyR2). Normally, RyR2 opening is tightly controlled by the trigger Ca2+ from L-type channels (CICR). But when SR Ca2+ load is excessive, RyR2 channels become hypersensitive and can open spontaneously without a trigger. This creates Ca2+ "sparks" that can coalesce into propagating Ca2+ waves, activating NCX throughout the cell.
Digoxin toxicity: Digoxin inhibits Na+/K+-ATPase → increased intracellular Na+ → NCX can't extrude Ca2+ effectively → Ca2+ accumulates. Catecholamines: β-adrenergic stimulation increases Ca2+ entry through L-type channels and enhances SR Ca2+ uptake. Heart failure: Altered Ca2+ handling with increased diastolic Ca2+. Catecholaminergic polymorphic VT (CPVT): Mutations in RyR2 or calsequestrin cause pathological SR Ca2+ leak.
Faster heart rates mean more action potentials per minute, each bringing Ca2+ into the cell. If Ca2+ extrusion cannot keep pace with Ca2+ entry, intracellular Ca2+ accumulates progressively with each beat. This is why DAD-mediated arrhythmias (like digoxin toxicity or CPVT) are typically triggered by exercise or stress—tachycardia exacerbates the Ca2+ overload.
EADs: Occur during Phase 2-3 • Mechanism is L-type Ca2+ (or late Na+) reactivation • Associated with prolonged QT • Bradycardia-dependent (pause-dependent) • Classic arrhythmia: Torsades de Pointes • Treatment: increase heart rate, correct QT-prolonging factors.
DADs: Occur during Phase 4 • Mechanism is Ca2+ overload → spontaneous SR release → NCX current • Associated with Ca2+ excess states • Tachycardia-dependent (exercise-triggered) • Classic arrhythmias: digoxin toxicity, CPVT • Treatment: β-blockers, reduce Ca2+ load.
AF Begets AF: Electrical Remodeling
Why atrial fibrillation becomes progressively harder to treat
One of the most important concepts in arrhythmia pathophysiology is that AF itself creates conditions that perpetuate AF. This was elegantly demonstrated in the landmark studies by Wijffels et al., who coined the phrase "AF begets AF." The concept: the rapid atrial rates during AF trigger adaptive changes in ion channel expression and tissue architecture that make the atria more susceptible to sustained AF. Understanding this remodeling explains why early intervention is crucial.
During AF, atrial cells are activated at rates of 400-600 times per minute—far exceeding normal. Each activation brings Ca2+ into the cell. The cells experience sustained Ca2+ overload that, if not managed, would be lethal. The cells adapt by downregulating Ca2+ entry—but this adaptation has profound electrophysiological consequences.
Sustained elevated intracellular Ca2+ activates calcineurin, a Ca2+-dependent phosphatase. Calcineurin dephosphorylates NFAT (Nuclear Factor of Activated T-cells), allowing it to enter the nucleus. NFAT acts as a transcription factor that downregulates L-type Ca2+ channel expression (CACNA1C gene). This reduces Ca2+ entry, protecting the cell from overload—but also shortening the action potential.
Shorter action potential = shorter refractory period. Remember the wavelength equation: Wavelength = Conduction velocity × Refractory period. Shorter refractory period → shorter wavelength → more wavelets can coexist in the atria simultaneously. Multiple wavelet re-entry is the mechanism of sustained AF. Shorter wavelengths mean more circuits fit in the same space, making AF more stable and harder to terminate.
Remarkably quickly. Studies show significant changes within 24-48 hours of continuous AF. The refractory period shortens by 20-30%, and the action potential duration decreases substantially. This explains why AF that persists for even a few days becomes harder to cardiovert, and why early rhythm control is emphasized in guidelines.
Yes—but slowly. After cardioversion to sinus rhythm, the atrial electrophysiology gradually normalizes over days to weeks. This is why post-cardioversion antiarrhythmic drugs are important: they "buy time" while the atria recover. However, if AF recurs during this vulnerable period, remodeling progresses. After multiple cycles, the changes may become permanent. This is the basis for the classification of AF: paroxysmal → persistent → long-standing persistent → permanent.
The classic theory of sustained AF is the multiple wavelet hypothesis (Moe, 1962): AF is maintained by multiple small re-entrant circuits (wavelets) that continuously collide, extinguish, and regenerate throughout the atria. For AF to sustain, there must be enough wavelets present at any moment that statistical extinction of some doesn't terminate the rhythm.
Wavelength determines how many wavelets fit: shorter wavelength → more wavelets → more stable AF. Electrical remodeling shortens wavelength (by reducing ERP). Structural remodeling provides more circuitous pathways (effectively increasing the space available). Together, they create a substrate where multiple wavelets can coexist indefinitely.
A more contemporary model proposes that AF is maintained by a small number of high-frequency rotors (spiral waves) rather than random wavelets. These rotors act as "drivers" that emit high-frequency activation to the surrounding atria. The peripheral atrial tissue cannot conduct 1:1 at rotor frequencies, so the activation breaks into fibrillatory conduction. The fibrillation is organized at the source but appears chaotic peripherally.
Why this matters: If AF is driven by a few rotors, ablation of those specific sites could terminate AF. This is the basis for focal impulse and rotor modulation (FIRM) mapping. However, controversy exists: rotors may be spatially unstable, and ablation results have been mixed. The truth likely involves both mechanisms: stable rotors in some patients, multiple wavelet chaos in others.
Early rhythm control matters. The 2020 EAST-AFNET 4 trial showed that early rhythm control (within 1 year of diagnosis) reduced cardiovascular outcomes compared to rate control alone. The pathophysiological basis: preventing remodeling preserves the ability to maintain sinus rhythm. Once remodeling is established, rhythm control becomes progressively less effective. This is why AF classification matters: paroxysmal AF (self-terminating) represents early-stage disease with minimal remodeling; long-standing persistent AF represents advanced remodeling that is often irreversible.
Antiarrhythmic Drugs: The Vaughan Williams Classification
Each class targets a specific ion channel or receptor—and each has predictable effects and risks
Antiarrhythmic drugs work by modifying ion channel function to alter the substrate or trigger for arrhythmias. The Vaughan Williams classification organizes drugs by their primary mechanism: Class I (Na+ channel block), Class II (β-adrenergic block), Class III (K+ channel block/action potential prolongation), and Class IV (Ca2+ channel block). Understanding the mechanism of each class reveals why they work for specific arrhythmias and why they have specific proarrhythmic risks.
The fundamental challenge: the same ion channels that cause arrhythmias also maintain normal cardiac function. Every antiarrhythmic drug has the potential to cause arrhythmias (proarrhythmia) under certain conditions. Understanding the molecular mechanism allows prediction of both therapeutic and adverse effects.
Class I drugs bind to Na+ channels and reduce the number of available channels for Phase 0 depolarization. This slows the upstroke (dV/dtmax) and reduces conduction velocity. By slowing conduction in re-entry circuits, these drugs can convert unidirectional block to bidirectional block (terminating re-entry) or make the wavelength exceed the circuit length (re-entry cannot sustain).
Use-dependence (frequency-dependence): A critical property of Class I drugs is that they bind more effectively to channels that are open or inactivated than to channels in the resting (closed) state. Fast heart rates mean more channel openings → more drug binding → greater effect at fast rates. This is why Class I drugs preferentially suppress tachyarrhythmias while having less effect at normal heart rates.
Mechanism: Moderate Na+ channel block with intermediate binding/unbinding kinetics (time constant 1-10 sec). Also block K+ channels (IKr), which prolongs action potential duration and QT interval. Net effect: slowed conduction AND prolonged refractoriness.
Why QT prolongation: K+ channel block reduces repolarization current → plateau extends → action potential prolongs → QT prolongs. The combination of Na+ block (conduction slowing) and K+ block (ERP prolongation) increases wavelength, which can terminate re-entry. However, QT prolongation creates EAD risk → Torsades de Pointes.
Clinical considerations: Useful for both atrial and ventricular arrhythmias. Must monitor QT interval. Quinidine notoriously causes diarrhea (GI side effects) and cinchonism. Procainamide causes drug-induced lupus with chronic use. Disopyramide has strong anticholinergic effects (vagolytic) and negative inotropy.
Mechanism: Bind and unbind from Na+ channels rapidly (time constant <1 sec). Because binding is so brief, they have minimal effect on normal tissue at normal heart rates. However, they preferentially bind to inactivated channels—which predominate in depolarized (ischemic) tissue.
Why preferential ischemic effect: Ischemic tissue is partially depolarized (elevated extracellular K+). At depolarized potentials, Na+ channels spend more time in the inactivated state. Class Ib drugs bind preferentially to inactivated channels and dissociate slowly from depolarized tissue. This creates selective suppression of ischemic arrhythmias with minimal effect on normal myocardium.
Effect on APD: Class Ib drugs may actually shorten action potential duration (especially in Purkinje fibers) by blocking late Na+ current. They do not prolong QT and have minimal proarrhythmic risk.
Clinical considerations: Lidocaine is the classic IV agent for ventricular arrhythmias in the acute setting (MI, post-cardiac surgery). Mexiletine is the oral equivalent. Limited efficacy for atrial arrhythmias (atrial tissue has different Na+ channel kinetics).
Mechanism: Bind and unbind from Na+ channels very slowly (time constant 10-20+ sec). Because unbinding is so slow, the effect accumulates—even at normal heart rates, significant Na+ channel block persists. This produces marked conduction slowing (QRS widening) even at rest.
Why potent but dangerous: Class Ic drugs are the most potent Na+ channel blockers. They dramatically slow conduction, which is highly effective for converting and preventing atrial arrhythmias (especially AF and atrial flutter). However, the same conduction slowing can create proarrhythmia in damaged ventricles—slow conduction promotes re-entry in scarred tissue.
CAST trial: The Cardiac Arrhythmia Suppression Trial showed increased mortality with flecainide and encainide in post-MI patients despite effective PVC suppression. Mechanism: slow conduction in peri-infarct tissue created new re-entry circuits. Class Ic drugs are contraindicated in structural heart disease.
Clinical considerations: Highly effective for AF in patients with structurally normal hearts. "Pill in pocket" approach for paroxysmal AF. Must exclude coronary disease and significant LV dysfunction before use. Flecainide also has some K+ channel blocking effects.
β-blockers antagonize the effects of catecholamines (epinephrine, norepinephrine) on β-adrenergic receptors. In the heart, β1-receptors are coupled to Gs proteins that activate adenylyl cyclase, increasing cAMP. cAMP has multiple electrophysiological effects: it increases If (steepening Phase 4 slope), increases ICa,L (enhancing contractility and AV nodal conduction), and increases SR Ca2+ release (positive inotropy but also DAD risk).
By blocking β-receptors, these drugs reduce If (slowing SA node rate), reduce ICa,L (slowing AV nodal conduction and reducing contractility), and reduce Ca2+ overload (suppressing DADs).
Sinus rate reduction: Decreased If slows Phase 4 depolarization in SA node → slower heart rate. Useful for sinus tachycardia, inappropriate sinus tachycardia.
AV nodal slowing: Decreased ICa,L in AV node slows conduction and prolongs ERP. This is the basis for rate control in AF—the ventricular rate is determined by how many atrial impulses can traverse the AV node. Slower AV conduction = fewer impulses get through = lower ventricular rate.
Anti-ischemic effects: Reduced heart rate and contractility decrease myocardial oxygen demand, reducing ischemia-related arrhythmias.
Anti-catecholamine effects: Critically important for DAD-mediated arrhythmias (catecholaminergic polymorphic VT, digoxin toxicity) where catecholamines exacerbate Ca2+ overload. β-blockers are first-line therapy for CPVT.
Post-MI benefit: Multiple trials show mortality reduction with β-blockers after MI. Mechanism includes suppression of catecholamine-driven arrhythmias and reduced sudden cardiac death.
Class III drugs block K+ channels responsible for repolarization (primarily IKr, IKs). Reduced K+ current prolongs Phase 2 and 3 → prolonged action potential duration (APD) → prolonged effective refractory period (ERP). Longer ERP means tissue stays refractory longer, increasing wavelength and making re-entry circuits harder to sustain.
Why prolonged refractoriness terminates re-entry: Recall: Wavelength = Conduction velocity Ă— ERP. If ERP increases, wavelength increases. If wavelength exceeds circuit length, the re-entrant impulse encounters refractory tissue and terminates. This is the mechanism by which Class III drugs cardiovert AF and prevent recurrence.
Amiodarone is the most effective antiarrhythmic drug—and the most complex. It has effects spanning all four Vaughan Williams classes: Na+ channel block (Class I), β-blocking (Class II), K+ channel block (Class III, multiple channels), and Ca2+ channel block (Class IV). It also has antithyroid effects and blocks α-receptors.
Why amiodarone is uniquely effective: Its multi-channel action means it attacks arrhythmias through multiple mechanisms simultaneously. The K+ block prolongs refractoriness; the Na+ block slows conduction; the Ca2+/β-block reduces triggered activity. This makes it effective for nearly all arrhythmia types.
Why amiodarone has lower Torsades risk than "pure" Class III drugs: Despite significantly prolonging QT, amiodarone has relatively low Torsades risk. Possible explanations: its Na+ and Ca2+ channel blocking effects counter the EAD-promoting effects of K+ block; it blocks multiple K+ channel subtypes rather than just IKr; it has reverse use-dependence (greater effect at slower rates, but less extreme than pure IKr blockers).
Toxicity: The "dirty" pharmacology means extensive side effects: pulmonary fibrosis, hepatotoxicity, thyroid dysfunction (hyper or hypo), corneal deposits, photosensitivity, peripheral neuropathy. Long half-life (weeks to months) means toxicity persists long after discontinuation.
Sotalol combines non-selective β-blockade (both β1 and β2) with IKr block. This dual mechanism provides rate control (β-block) plus rhythm control (K+ block). It prolongs QT and has significant Torsades risk, especially with renal impairment (renally excreted), hypokalemia, or bradycardia.
Dofetilide: Selective IKr blocker for AF/flutter cardioversion and maintenance. Requires in-hospital initiation with telemetry monitoring due to Torsades risk. QT must be monitored; drug must be discontinued if QT exceeds limits. Renally excreted—requires dose adjustment for renal function.
Ibutilide: IV agent for acute cardioversion of AF/flutter. Enhances slow inward Na+ current in addition to IKr block—both prolong APD. High conversion rates for recent-onset AF but significant Torsades risk (must monitor for 4-6 hours post-infusion).
Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) block L-type Ca2+ channels in the heart. Their primary electrophysiological effect is on nodal tissue (SA and AV nodes), where L-type Ca2+ channels mediate Phase 0 depolarization (unlike working myocardium, which uses Na+ channels).
Effects: In SA node: reduced Phase 4 slope → slower heart rate. In AV node: slowed Phase 0 upstroke → slowed conduction → prolonged AV nodal ERP. The AV nodal effect is the basis for rate control in AF and termination of AVNRT.
Nodal cells have low Na+ channel density; their Phase 0 depends on L-type Ca2+ channels. Working myocardium has abundant Na+ channels and uses Ca2+ channels primarily for plateau (Phase 2) and excitation-contraction coupling. Thus, L-type Ca2+ blockers have profound effects on nodal conduction but relatively modest effects on atrial/ventricular depolarization.
Verapamil vs Diltiazem: Verapamil has more potent negative inotropic effect (greater myocardial depression). Diltiazem has more vasodilation. Both are effective for rate control and AVNRT termination.
Rate control in AF: AV nodal slowing limits ventricular response to rapid atrial activation. Often combined with β-blockers but with caution (additive bradycardia, negative inotropy).
AVNRT termination: IV verapamil or diltiazem can terminate AVNRT by blocking the slow AV nodal pathway (which is Ca2+-dependent).
WARNING in WPW with AF: Class IV drugs (and β-blockers, and digoxin) are contraindicated in AF with pre-excitation (WPW). These drugs slow AV nodal conduction but have no effect on accessory pathway conduction. By blocking the AV node, more impulses conduct down the accessory pathway → rapid ventricular rates → potential degeneration to VF. Use procainamide or ibutilide instead.
Mechanism: Activates A1 adenosine receptors on nodal cells. This activates IK,Ado (adenosine-activated K+ current), hyperpolarizing the cell and dramatically slowing AV nodal conduction. Half-life is seconds (metabolized by red blood cells).
Use: First-line for terminating AVNRT and AVRT. The ultra-short duration makes it safe—if it doesn't work or causes transient side effects (flushing, dyspnea, chest pressure), effects resolve in seconds. Also useful diagnostically: unmasking atrial flutter waves by creating transient AV block.
Contraindication: Like CCBs, adenosine is dangerous in pre-excited AF (WPW) because it blocks AV node but not accessory pathway.
Mechanism: Inhibits Na+/K+-ATPase → increased intracellular Na+ → NCX cannot extrude Ca2+ efficiently → increased intracellular Ca2+ → positive inotropy. Also has vagotonic effects (enhances parasympathetic tone to AV node), slowing AV conduction.
Use: Rate control in AF, particularly with heart failure (where β-blockers/CCBs may worsen hemodynamics). The vagotonic effect provides AV nodal slowing; the positive inotropy supports cardiac output.
Toxicity: Narrow therapeutic index. Toxicity causes DAD-mediated arrhythmias (accelerated junctional rhythm, bidirectional VT) due to Ca2+ overload. Exacerbated by hypokalemia (K+ competes with digoxin at Na+/K+-ATPase) and hypercalcemia.
Mechanism: Selective If blocker. Reduces the slope of Phase 4 depolarization in SA node without affecting contractility, conduction, or repolarization. Pure "sinus rate reduction" without other hemodynamic effects.
Use: Heart rate reduction in chronic heart failure (SHIFT trial showed reduced HF hospitalization). Also used for inappropriate sinus tachycardia. Not effective for AF rate control (AF doesn't involve If).
All antiarrhythmic drugs can cause arrhythmias under certain conditions. Class Ia and III drugs prolong QT → Torsades de Pointes (especially with bradycardia, hypokalemia, hypomagnesemia). Class Ic drugs slow conduction → facilitate re-entry in scarred ventricles (CAST trial). Class I drugs in AF can organize AF into atrial flutter with 1:1 conduction (flutter waves conduct more easily than fibrillation). Always assess the risk-benefit ratio, optimize electrolytes, and consider patient-specific factors (structural heart disease, renal function, drug interactions).
Clinical Integration: From Mechanism to Management
Connecting pathophysiology to therapeutic decisions
Understanding arrhythmia mechanisms transforms management from protocol-following to rational decision-making. When you understand why an arrhythmia occurs, you can predict which interventions will work and which might cause harm. The goal is to match the mechanism to the treatment.
-
Re-entry
Goal: Eliminate one of the three requirements (circuit, unidirectional block, excitable gap).
Catheter ablation: Destroys critical part of circuit (most definitive).
Class I drugs: Slow conduction → convert unidirectional block to bidirectional block, or increase wavelength beyond circuit length.
Class III drugs: Prolong refractoriness → increase wavelength → re-entry cannot sustain.
Overdrive pacing: Captures excitable gap, terminates re-entry. -
Abnormal Automaticity
Goal: Suppress the ectopic pacemaker or correct the underlying cause.
β-blockers: Reduce catecholamine drive, slow Phase 4 depolarization.
Correct underlying cause: Treat ischemia, normalize electrolytes, reduce catecholamines.
Note: Overdrive pacing is often ineffective (automatic foci may not suppress).
Catheter ablation: Can target focal automatic sources. -
EAD-Triggered (Torsades)
Goal: Shorten the action potential, eliminate pauses, correct predisposing factors.
Increase heart rate: Isoproterenol or pacing (shortens APD, eliminates pauses).
IV magnesium: Stabilizes membrane, suppresses EADs (even with normal Mg2+ levels).
Stop QT-prolonging drugs: Remove the precipitant.
Correct K+: Target K+ >4.0 mEq/L (low K+ prolongs QT). -
DAD-Triggered (Ca2+ Overload)
Goal: Reduce intracellular Ca2+, suppress triggered activity.
β-blockers: Reduce Ca2+ entry and SR Ca2+ release. First-line for CPVT.
Verapamil: Reduces Ca2+ entry through L-type channels.
Treat underlying cause: Digoxin antibody for digoxin toxicity; reduce catecholamines.
Avoid rapid pacing: May exacerbate Ca2+ overload.
The Vaughan Williams classification, while clinically useful, oversimplifies drug actions. The Sicilian Gambit (1991) proposed a more comprehensive framework that considers all the ion channels, receptors, and pumps affected by each drug. This approach recognizes that most antiarrhythmics have multiple actions and that selecting a drug should be based on matching its electrophysiological effects to the vulnerable parameter of the specific arrhythmia.
Vulnerable parameters: Each arrhythmia mechanism has a vulnerable parameter that, if modified, terminates the arrhythmia. For re-entry: conduction velocity, refractory period, or circuit integrity. For automaticity: Phase 4 slope. For triggered activity: action potential duration (EADs) or intracellular Ca2+ (DADs). Rational therapy targets the vulnerable parameter.
Step 1: Identify the arrhythmia. Regular vs irregular? Narrow vs wide QRS? Atrial vs ventricular?
Step 2: Determine the mechanism. Re-entry (most common for regular sustained tachycardias)? Automaticity (ectopic foci, escape rhythms)? Triggered activity (long QT, digoxin toxicity)?
Step 3: Identify the substrate. Structural heart disease? Channelopathy? Electrolyte abnormality? Drug effect?
Step 4: Select therapy based on mechanism. Match the intervention to the vulnerable parameter.
Step 5: Consider proarrhythmic risk. Does the therapy create new risks? Is there structural heart disease that contraindicates certain drugs?
Cardiac arrhythmias are not random electrical storms—they are the predictable consequences of specific molecular and cellular dysfunctions. Ion channels form the foundation: their coordinated opening and closing creates the action potential. When channels fail (through genetic mutation, ischemia, drugs, or remodeling), the action potential changes, creating substrates for arrhythmia.
Re-entry requires a circuit, unidirectional block, and an excitable gap. Understanding this triad reveals why ablation, conduction-slowing drugs, and refractoriness-prolonging drugs all work—each eliminates one requirement. Abnormal automaticity occurs when non-pacemaker cells develop Phase 4 depolarization, typically due to partial depolarization. Triggered activity reflects afterdepolarizations—EADs from prolonged repolarization (long QT) and DADs from Ca2+ overload.
The concept that "AF begets AF" illustrates how arrhythmias modify their own substrate through electrical and structural remodeling. This vicious cycle explains the natural history of AF progression and underscores the importance of early intervention. Antiarrhythmic drugs work by modifying ion channel function—but the same modifications that suppress arrhythmias can create new ones under different conditions. Understanding the mechanism allows rational drug selection and risk mitigation.
The deep pathophysiology of arrhythmias is not academic—it is clinically essential. Every therapeutic decision is ultimately a decision about ion channels and action potentials. When we understand the "why of the why," arrhythmia management becomes not just protocol adherence, but true clinical reasoning.
"The rhythm of the heart reflects the molecular harmony of its ion channels. Arrhythmias are not chaos—they are order gone wrong, and understanding their mechanism reveals the path to restoration."
— The Principle of Mechanistic Electrophysiology
January CT, et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation 2014 • Al-Khatib SM, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias. Circulation 2018 • Hindricks G, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. Eur Heart J 2021 • Zipes DP, Jalife J. Cardiac Electrophysiology: From Cell to Bedside. 7th ed. Elsevier 2018 • Antzelevitch C, Bhugian J, et al. Brugada syndrome: Report of the second consensus conference. Circulation 2005 • Wijffels MC, et al. Atrial fibrillation begets atrial fibrillation. Circulation 1995 • Nattel S, Bhugra M, et al. Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy. Circ Res 2020 • Roden DM. Drug-Induced Prolongation of the QT Interval. NEJM 2004 • Echt DS, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo (CAST). NEJM 1991 • Kirchhof P, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation (EAST-AFNET 4). NEJM 2020 • Grant AO. Cardiac Ion Channels. Circ Arrhythm Electrophysiol 2009